Javier Glez‐Vaz

687 total citations
17 papers, 372 citations indexed

About

Javier Glez‐Vaz is a scholar working on Immunology, Oncology and Infectious Diseases. According to data from OpenAlex, Javier Glez‐Vaz has authored 17 papers receiving a total of 372 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 14 papers in Oncology and 1 paper in Infectious Diseases. Recurrent topics in Javier Glez‐Vaz's work include CAR-T cell therapy research (13 papers), Immunotherapy and Immune Responses (12 papers) and Immune Cell Function and Interaction (8 papers). Javier Glez‐Vaz is often cited by papers focused on CAR-T cell therapy research (13 papers), Immunotherapy and Immune Responses (12 papers) and Immune Cell Function and Interaction (8 papers). Javier Glez‐Vaz collaborates with scholars based in Spain, United Kingdom and United States. Javier Glez‐Vaz's co-authors include Ignacio Melero, Álvaro Teijeira, Iñaki Etxeberría, Miguel F. Sanmamed, Carlos Luri‐Rey, Jun Wang, Lieping Chen, Maite Álvarez, Pedro Berraondo and Irene Olivera and has published in prestigious journals such as Hepatology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Javier Glez‐Vaz

17 papers receiving 368 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Javier Glez‐Vaz Spain 11 245 229 91 32 30 17 372
Annelisa M. Cornel Netherlands 9 229 0.9× 245 1.1× 164 1.8× 27 0.8× 26 0.9× 16 439
Marte Fauskanger Norway 10 378 1.5× 310 1.4× 138 1.5× 21 0.7× 32 1.1× 11 525
Annika De Sousa Linhares Austria 7 212 0.9× 270 1.2× 95 1.0× 42 1.3× 42 1.4× 11 400
Michael Korrer United States 7 291 1.2× 197 0.9× 79 0.9× 14 0.4× 17 0.6× 16 361
Irina Ganeeva Russia 9 132 0.5× 216 0.9× 130 1.4× 51 1.6× 27 0.9× 16 344
Lieke L. van der Woude Netherlands 6 187 0.8× 212 0.9× 77 0.8× 38 1.2× 42 1.4× 10 306
Kelli A. Connolly United States 6 312 1.3× 305 1.3× 113 1.2× 24 0.8× 56 1.9× 13 479
Alejandro Alice United States 11 439 1.8× 440 1.9× 122 1.3× 34 1.1× 43 1.4× 18 606
Iñaki Eguren‐Santamaría Spain 7 223 0.9× 203 0.9× 83 0.9× 31 1.0× 97 3.2× 17 394
Andressa S. Laino United States 11 273 1.1× 382 1.7× 204 2.2× 28 0.9× 56 1.9× 20 582

Countries citing papers authored by Javier Glez‐Vaz

Since Specialization
Citations

This map shows the geographic impact of Javier Glez‐Vaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Glez‐Vaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Glez‐Vaz more than expected).

Fields of papers citing papers by Javier Glez‐Vaz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javier Glez‐Vaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Glez‐Vaz. The network helps show where Javier Glez‐Vaz may publish in the future.

Co-authorship network of co-authors of Javier Glez‐Vaz

This figure shows the co-authorship network connecting the top 25 collaborators of Javier Glez‐Vaz. A scholar is included among the top collaborators of Javier Glez‐Vaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier Glez‐Vaz. Javier Glez‐Vaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Azpilikueta, Arantza, et al.. (2024). CD137 (4-1BB) and T-Lymphocyte Exhaustion. Clinical Cancer Research. 30(18). 3971–3973. 1 indexed citations
2.
Mancheño, Uxua, Javier Glez‐Vaz, Ibón Tamayo, et al.. (2024). Human T cells engineered with an HLA-A2-restricted murine T-cell receptor targeting glypican 3 effectively control human hepatocellular carcinoma in mice. Hepatology. 82(2). 326–343. 2 indexed citations
3.
Olivera, Irene, Elixabet Bolaños, Sandra Hervás‐Stubbs, et al.. (2023). mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy. Cell Reports Medicine. 4(3). 100978–100978. 32 indexed citations
4.
Luri‐Rey, Carlos, et al.. (2023). Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming. Immunological Reviews. 321(1). 143–151. 10 indexed citations
5.
Álvarez, Maite, Carmen Molina, Saray Garasa, et al.. (2023). Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic. OncoImmunology. 12(1). 2197370–2197370. 10 indexed citations
6.
Glez‐Vaz, Javier, Arantza Azpilikueta, María C. Ochoa, et al.. (2023). CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects. Science Advances. 9(33). eadf6692–eadf6692. 6 indexed citations
7.
Ochoa, María C., Carlos E. de Andrea, Saray Garasa, et al.. (2023). Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma. Cell Reports Medicine. 4(4). 101009–101009. 16 indexed citations
8.
Cirella, Assunta, Elixabet Bolaños, Carlos Luri‐Rey, et al.. (2023). Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists. Molecular Therapy — Nucleic Acids. 33. 668–682. 6 indexed citations
9.
Glez‐Vaz, Javier, Arantza Azpilikueta, Irene Olivera, et al.. (2022). Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. Journal for ImmunoTherapy of Cancer. 10(3). e003532–e003532. 13 indexed citations
10.
Melero, Ignacio, Miguel F. Sanmamed, Javier Glez‐Vaz, et al.. (2022). CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary. Cancer Discovery. 13(3). 552–569. 51 indexed citations
11.
Glez‐Vaz, Javier, Arantza Azpilikueta, Irene Olivera, et al.. (2022). Abstract 628: Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. Cancer Research. 82(12_Supplement). 628–628. 1 indexed citations
12.
Olivera, Irene, Elixabet Bolaños, Sandra Hervás‐Stubbs, et al.. (2022). 267 mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy. Regular and Young Investigator Award Abstracts. A282–A282. 1 indexed citations
13.
Álvarez, Maite, Carmen Molina, Carlos E. de Andrea, et al.. (2021). Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. Journal for ImmunoTherapy of Cancer. 9(11). e002953–e002953. 29 indexed citations
14.
Teijeira, Álvaro, Saray Garasa, María C. Ochoa, et al.. (2021). Differential Interleukin‐8 thresholds for chemotaxis and netosis in human neutrophils. European Journal of Immunology. 51(9). 2274–2280. 41 indexed citations
15.
Mancheño, Uxua, Javier Glez‐Vaz, Noëlia Casares, et al.. (2021). Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants. Journal for ImmunoTherapy of Cancer. 9(11). e003351–e003351. 39 indexed citations
16.
Salas‐Benito, Diego, et al.. (2020). Inflammation and immunity in ovarian cancer. European Journal of Cancer Supplements. 15. 56–66. 18 indexed citations
17.
Etxeberría, Iñaki, Javier Glez‐Vaz, Álvaro Teijeira, & Ignacio Melero. (2019). New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis. ESMO Open. 4(Suppl 3). e000733–e000733. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annelisa M. Cornel Breakdown of academic impact, for papers by Marte Fauskanger Breakdown of academic impact, for papers by Annika De Sousa Linhares Breakdown of academic impact, for papers by Michael Korrer Breakdown of academic impact, for papers by Irina Ganeeva Breakdown of academic impact, for papers by Lieke L. van der Woude Breakdown of academic impact, for papers by Kelli A. Connolly Breakdown of academic impact, for papers by Alejandro Alice Breakdown of academic impact, for papers by Iñaki Eguren‐Santamaría Breakdown of academic impact, for papers by Andressa S. Laino
Rankless by CCL
2026